کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5664138 | 1590705 | 2017 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Enzastaurin: A lesson in drug development Enzastaurin: A lesson in drug development](/preview/png/5664138.png)
- The development of the proposed anticancer drug Enzastaurin is reviewed.
- Protein Kinase C structure and function are discussed with a focus on isozyme specific inhibitors.
- Enzastaurin's molecular mechanisms are examined.
- Enzastaurin's preclinical and clinical efficacies are scrutinized.
- Challenges associated with drug development are explored.
Enzastaurin is an orally administered drug that was intended for the treatment of solid and haematological cancers. It was initially developed as an isozyme specific inhibitor of protein kinase Cβ (PKCβ), which is involved in both the AKT and MAPK signalling pathways that are active in many cancers. Enzastaurin had shown encouraging preclinical results for the prevention of angiogenesis, inhibition of proliferation and induction of apoptosis as well as showing limited cytotoxicity within phase I clinical trials. However, during its assessment in phase II and III clinical trials the efficacy of enzastaurin was poor both in combination with other drugs and as a single agent. In this review, we will discuss the development of enzastaurin from drug design to clinical testing, exploring target identification, validation and preclinical assessment. Finally, we will consider the clinical evaluation of enzastaurin as an example of the challenges associated with drug development. In particular, we discuss the poor translation of drug efficacy from preclinical animal models, inappropriate end point analysis, limited standards in phase I clinical trials, insufficient use of biomarker analysis and also patient stratification, all of which contributed to the failure to achieve approval of enzastaurin as an anticancer therapeutic.
Journal: Critical Reviews in Oncology/Hematology - Volume 112, April 2017, Pages 72-79